The Astressin Disease Platform:
Astressins have the potential to modulate the autonomic, behavioral, endocrine, visceral, immune and reproductive responses to stress and therefore have broad applicability to treat multiple stress-related diseases. Indeed, the influence of stress may be as far reaching as effects on cancer. The astressins are currently poised to enter into preclinical IND-enabling studies and upon successful completion Sentia plans to move these compounds into clinical testing. Sentia has initially prioritized gastrointestinal diseases and orphan endocrine diseases resulting from dysregulation of the hypothalamic-pituitary-adrenal axis (HPA). Many of these initial diseases share overlapping physiology allowing the company to efficiently capitalize on success in any one of the prioritized areas.